initial public offerings (IPOs) trading on American exchanges

Saturday, April 21, 2018

MorphoSys AG (MOR) began trading on the Nasdaq on 19 April 2018

MorphoSys AG is a German biotechnology company. It is involved in the development and research of antibodies. TecDAX has listed MorphoSys since 2004.
  • Headquarters: Planegg, Germany
  • Number of employees: 460 (end 2010)
  • Founded: 1992, Martinsried, Germany
MorphoSys raised upwards of $207.8 million. The company says it’s gathering resources to sink $225 million into the development of its investigational anti-CD19 antibody MOR208 -- a drug it’s developing for diffuse large B cell lymphoma (DLBCL).  After its last batch of upbeat data from a Phase II study, MorphoSys, which already received breakthrough status for the drug, said it went straight to regulators hoping for early approval.

No comments:

Post a Comment